Development of Computational Approaches for Medical Image Retrieval, Disease Gene Prediction, and Drug Discovery

Total Page:16

File Type:pdf, Size:1020Kb

Development of Computational Approaches for Medical Image Retrieval, Disease Gene Prediction, and Drug Discovery DEVELOPMENT OF COMPUTATIONAL APPROACHES FOR MEDICAL IMAGE RETRIEVAL, DISEASE GENE PREDICTION, AND DRUG DISCOVERY by YANG CHEN Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Dr. Rong Xu, Dr. Guo-qiang Zhang Department of Electrical Engineering and Computer Science CASE WESTERN RESERVE UNIVERSITY August 2015 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Yang Chen candidate for the degree of Doctor of Philosophy∗ Committee Chair Guo-qiang Zhang Committee Member Rong Xu Committee Member Jing Li Committee Member M. Cenk Cavusoglu Committee Member Xiang Zhang Date of Defense June 23, 2015 *We also certify that written approval has been obtained for any proprietary material contained therein. iii Contents 1 Introduction 1 1.1 Domain knowledge guided strategy for developing computational approaches for biomedical applications ................. 1 1.2 Retrieving medically-relevant web images ................ 3 1.3 Detecting novel genetic basis for human diseases ............ 4 1.4 Predicting novel drug treatments based on disease genetics ...... 7 1.5 Contribution and organization of the dissertation ........... 8 2 Ontology guided approach to retrieving medically-relevant web images: application on retrieving disease manifestation images 10 2.1 Motivation .................................. 10 2.2 Data and methods .............................. 12 2.2.1 Discovering target body parts ................... 12 2.2.2 Detecting target body parts .................... 14 2.2.3 Combining detections for disease image classification ..... 16 2.3 Results .................................... 17 2.3.1 Single-organ disease classification ................ 17 2.3.2 Multiple-organ disease classification ............... 20 2.4 Discussion .................................. 23 2.5 Conclusions ................................. 25 iv 3 Analyzing cross-species genetic networks to predict disease-associated genes: application on Plasmodium falciparum malaria 27 3.1 Motivation .................................. 27 3.2 Data and methods .............................. 29 3.2.1 Construct cross-species gene network .............. 30 3.2.2 Predict candidate genes for malaria ............... 30 3.2.3 Evaluate the validity in predicting malaria genes ....... 32 3.2.4 Evaluate the ranks of druggable genes .............. 32 3.2.5 Extract and analyze malaria-specific pathways based on gene ranking ................................ 33 3.3 Results .................................... 33 3.3.1 Network-based approach allows the prioritization of known malaria genes from both human and parasite genomes .... 33 3.3.2 Network-based approach prioritizes novel malaria genes other than the seeds ............................ 34 3.3.3 Prioritized genes are enriched by druggable genes ....... 36 3.3.4 Pathway analysis shows functions of prioritized genes .... 37 3.4 Discussion .................................. 38 3.5 Conclusions ................................. 40 4 Combining multiple human phenotype networks to predict disease-associated genes: application on Crohn’s disease 41 4.1 Motivation .................................. 41 4.2 Data and methods .............................. 43 4.2.1 Construct DMN using disease-manifestation associations in UMLS ................................ 44 4.2.2 Compare phenotypic relationships in DMN with genetic dis- ease associations .......................... 46 v 4.2.3 Compare DMN with the widely-used disease phenotype net- work mimMiner .......................... 48 4.2.4 Integrate networks ......................... 48 4.2.5 Predict disease genes from the integrated network ....... 49 4.2.6 Evaluate gene prediction in cross validation analyses ..... 51 4.2.7 Evaluate gene prediction for different disease classes ..... 53 4.2.8 Investigate translational potential in drug discovery of the predicted genes for Crohn’s disease ............... 53 4.3 Results .................................... 54 4.3.1 DMN network properties ..................... 54 4.3.2 DMN partially correlates with the genetic disease networks . 57 4.3.3 DMN contains knowledge different from mimMiner ..... 59 4.3.4 Integrating DMN with mimMiner significantly improves the performance of disease gene predictions ............ 60 4.3.5 Our method achieves high but varying performance for dif- ferent disease classes ........................ 62 4.3.6 Our gene prediction method has the potential to guide the drug discovery for Crohn’s disease ................ 64 4.4 Discussion .................................. 67 4.5 Conclusions ................................. 68 5 Studying disease comorbidity network to detect genetic evidences for disease links: application on colorectal cancer and obesity 69 5.1 Motivation .................................. 69 5.2 Data and methods .............................. 71 5.2.1 Construct disease comorbidity network ............. 71 5.2.2 Prioritize the diseases that have strong associations with both obesity and CRC .......................... 75 vi 5.2.3 Identify gene overlaps through gene expression meta-analysis 76 5.3 Results .................................... 77 5.3.1 Local disease comorbidity network models the connection between obesity and CRC ..................... 77 5.3.2 Osteoporosis shows high comorbidity associations with both CRC and obesity .......................... 77 5.3.3 Innovative genes shared among osteoporosis, obesity and CRC are detected using gene expression meta-analysis .... 79 5.4 Discussion .................................. 80 5.5 Conclusions ................................. 81 6 Combing human disease genetics and mouse model phenotypes towards drug repositioning: application on Parkinson’s disease 83 6.1 Motivation .................................. 83 6.2 Data and methods .............................. 85 6.2.1 Identify mouse model phenotypes for PD using disease ge- netics in OMIM ........................... 85 6.2.2 Prioritize candidate PD drugs based on the similarities of mouse phenotype profiles between disease and drugs .... 87 6.2.3 De novo evaluation in prioritizing FDA-approved PD drugs 88 6.2.4 Evaluation in ranking novel PD drugs and comparison with an existing drug repositioning approach ............. 90 6.2.5 Test the top-ranked drugs using gene expression data analysis 91 6.3 Results .................................... 91 6.3.1 Our disease genetics-based phenotype prioritization algorithm identified PD-specific mouse model phenotypes ........ 91 6.3.2 Our approach prioritized FDA-approved PD drugs ...... 92 vii 6.3.3 Our approach outperformed an existing approach in priori- tizing novel PD drugs ....................... 94 6.3.4 Gene expression analysis suggests quetiapine as a potential PD drug ............................... 96 6.4 Discussion .................................. 96 6.5 Conclusions ................................. 97 7 Conclusions and future work 98 7.1 Conclusions ................................. 98 7.2 Future work ................................. 100 7.2.1 Disease image retrieval ...................... 100 7.2.2 Disease gene prediction ...................... 100 7.2.3 Drug repositioning ......................... 101 Appendices viii List of Tables 2.1 Performance Comparison on Ten Eye Disease Image Test Sets. .... 19 2.2 Performance Comparison on Ten Ear Disease Image Test Sets. .... 21 2.3 Performance Comparison on Ten Mouth/Lip Disease Image Test Sets. 22 2.4 Performance Comparison on Ten Mouth/Lip Disease Image Test Sets. 24 3.1 Result of the leave-one-out cross validation for human genes. We left out one malaria gene from the seed list each time, and deter- mined the rank of this excluded gene using our method. We showed the rank and percentage among all human genes. ........... 35 3.2 Top 10 parasite genes in the leave-one-out cross validation. ...... 35 3.3 Rank of other malaria-associated genes from literature. ........ 36 3.4 Pathways prioritized over 50% in rank. ................. 39 4.1 Global properties of DMN and the other disease networks, includ- ing HDNs (genetic disease networks) and mimMiner (widely-used phenotype network) based on OMIM text mining. The last three columns represent average shortest path, average cluster coefficient, and connected component, respectively. ................. 55 ix 4.2 Compare the edge overlaps N between DMN and the genetic dis- 0 ease networks. Network B represents the randomized graph that 0 preserves the properties of Network B. Column N(A;B ) represents the average number of edge overlap comparing network A and the randomized networks. ........................... 58 4.3 Compare the community structures between DMN and the genetic disease networks. SA!B and SB!A represent the two-way the simi- larity in community partitions between network A and B. ...... 59 4.4 Compare DMN with mimMiner in nodes, edges and community structures. .................................. 60 4.5 Ratios of successful disease-gene association predictions in the leave- one-out cross validation experiment. All diseases were included in the experiment. ............................... 61 4.6 Success ratio of disease-gene association predictions for all diseases and monogenetic diseases in the nine disease classes. ......... 63 4.7 Drug candidates for Crohn’s disease that are supported by literature. 66 5.1 Top five disease nodes in the local network that contains all paths from obesity to colorectal cancer. the diseases were ranked by de- gree and betweenness,
Recommended publications
  • The Role of Nuclear Lamin B1 in Cell Proliferation and Senescence
    Downloaded from genesdev.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press The role of nuclear lamin B1 in cell proliferation and senescence Takeshi Shimi,1 Veronika Butin-Israeli,1 Stephen A. Adam,1 Robert B. Hamanaka,2 Anne E. Goldman,1 Catherine A. Lucas,1 Dale K. Shumaker,1 Steven T. Kosak,1 Navdeep S. Chandel,2 and Robert D. Goldman1,3 1Department of Cell and Molecular Biology, 2Department of Medicine, Division of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA Nuclear lamin B1 (LB1) is a major structural component of the nucleus that appears to be involved in the regulation of many nuclear functions. The results of this study demonstrate that LB1 expression in WI-38 cells decreases during cellular senescence. Premature senescence induced by oncogenic Ras also decreases LB1 expression through a retinoblastoma protein (pRb)-dependent mechanism. Silencing the expression of LB1 slows cell proliferation and induces premature senescence in WI-38 cells. The effects of LB1 silencing on proliferation require the activation of p53, but not pRb. However, the induction of premature senescence requires both p53 and pRb. The proliferation defects induced by silencing LB1 are accompanied by a p53-dependent reduction in mitochondrial reactive oxygen species (ROS), which can be rescued by growth under hypoxic conditions. In contrast to the effects of LB1 silencing, overexpression of LB1 increases the proliferation rate and delays the onset of senescence of WI-38 cells. This overexpression eventually leads to cell cycle arrest at the G1/S boundary.
    [Show full text]
  • SPEN Induces Mir-4652-3P to Target HIPK2 in Nasopharyngeal Carcinoma
    Li et al. Cell Death and Disease (2020) 11:509 https://doi.org/10.1038/s41419-020-2699-2 Cell Death & Disease ARTICLE Open Access SPEN induces miR-4652-3p to target HIPK2 in nasopharyngeal carcinoma Yang Li1,YuminLv1, Chao Cheng2,YanHuang3,LiuYang1, Jingjing He1,XingyuTao1, Yingying Hu1,YutingMa1, Yun Su1,LiyangWu1,GuifangYu4, Qingping Jiang5,ShuLiu6,XiongLiu7 and Zhen Liu1 Abstract SPEN family transcriptional repressor (SPEN), also known as the SMART/HDAC1-associated repressor protein (SHARP), has been reported to modulate the malignant phenotypes of breast cancer, colon cancer, and ovarian cancer. However, its role and the detail molecular basis in nasopharyngeal carcinoma (NPC) remain elusive. In this study, the SPEN mRNA and protein expression was found to be increased in NPC cells and tissues compared with nonmalignant nasopharyngeal epithelial cells and tissues. Elevated SPEN protein expression was found to promote the pathogenesis of NPC and lead to poor prognosis. Knockdown of SPEN expression resulted in inactivation ofPI3K/AKT and c-JUN signaling, thereby suppressing NPC migration and invasion. In addition, miR-4652-3p was found to be a downstream inducer of SPEN by targeting the homeodomain interacting protein kinase 2 (HIPK2) gene, a potential tumor suppressor that reduces the activation of epithelial–mesenchymal transition (EMT) signaling, thereby reducing its expression and leading to increased NPC migration, invasion, and metastasis. In addition, SPEN was found to induce miR-4652-3p expression by activating PI3K/AKT/c-JUN signaling to target HIPK2. Our data provided a new molecular mechanism for SPEN as a metastasis promoter through activation of PI3K/AKT signaling, thereby stimulating the c-JUN/miR-4652-3p axis to target HIPK2 in NPC.
    [Show full text]
  • Isoforms, Structures, and Functions of Versatile Spectraplakin MACF1
    BMB Rep. 2016; 49(1): 37-44 BMB www.bmbreports.org Reports Contiributed Mini Review Isoforms, structures, and functions of versatile spectraplakin MACF1 Lifang Hu1, Peihong Su1, Runzhi Li1, Chong Yin1, Yan Zhang1, Peng Shang1, Tuanmin Yang2 & Airong Qian1,* 1Key Laboratory for Space Bioscience and Biotechnology, Institute of Special Environmental Biophysics, School of Life Sciences, Northwestern Polytechnical University, Xi’an, Shaanxi 710072, 2Honghui Hospital, Xi’an Jiaotong University College of Medicine, Xi’an, Shaanxi 710054, P. R. China Spectraplakins are crucially important communicators, linking ability of interacting with all three types of cytoskeletal fila- cytoskeletal components to each other and cellular junctions. ments, i.e., F-actin, MTs, and IFs (1). Microtubule actin crosslinking factor 1 (MACF1), also known Spectraplakins are exceptionally long and gigantic with mo- as actin crosslinking family 7 (ACF7), is a member of the spec- lecular weight of >500 kD. They are multi-domain cytoskele- traplakin family. It is expressed in numerous tissues and cells tal proteins and master orchestrators for coordinating cytoske- as one extensively studied spectraplakin. MACF1 has several letal elements by binding to F-actin, MTs, and IFs (1, 2). isoforms with unique structures and well-known function to be Spectraplakins are evolutionarily conserved. They belong to able to crosslink F-actin and microtubules. MACF1 is one ver- both spectrin and plakin superfamilies (3). “Spectraplakins” are satile spectraplakin with various functions in cell processes, named as combinations of “spectrin” and “plakin” because embryo development, tissue-specific functions, and human they share features of both spectrins and plakins (3, 4). So far, diseases. The importance of MACF1 has become more appa- mammalian spectraplakins have two members: microtubule rent in recent years.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,981,727 Baden Et Al
    USOO5981727A United States Patent (19) 11 Patent Number: 5,981,727 Baden et al. (45) Date of Patent: Nov. 9, 1999 54 PLANT GROUP 2 PROMOTERS AND USES OTHER PUBLICATIONS THEREOF Oommen et al (1994) The Plant Cell 6: 1789–1803. 75 Inventors: Catherine S. Baden, Martinez, Pamela Lewin, (1985) In: Genes II, Wiley and Sons, NY, pp. Dunsmuir, Piedmont; Kathleen Y. Lee, 182-183. Oakland, all of Calif. Van Haaven et al (1991) Plant Mol Biol 17: 615-630. 73 Assignee: DNA Plant Technology Corporation, Pear et al (1989) Plant Mol Biol 13: 639-651. Oakland, Calif. Primary Examiner Elizabeth F. McElwain 21 Appl. No.: 08/761,549 Attorney, Agent, or Firm Townsend and Townsend and 22 Filed: Dec. 6, 1996 Crew Related U.S. Application Data 57 ABSTRACT This invention relates to compositions and methods useful in 63 Continuation of application No. 08/289,458, Aug. 12, 1994, the production of transgenic plants. In particular, the inven Pat. No. 5,608,144. tion relates to Group 2 (Gp2) plant promoter Sequences and 51 Int. Cl. ............................ C12N 15700;s CO7H 21/04 to expressionp cassettes containingg Gp2Op.4 planlplant ppromoter 52 U.S. Cl. ...................... 536/23.6; 536/24.1; 435/1723 Sequences. The invention also relates to vectors and trans 58 Field of Search ........................... 800/205; 435/69.1, genic plants containing Gp2 plant promoter Sequences that 435/172.3, 419, 536/24.1, 23.6 are operably linked to heterologous DNA sequences. In addition, the invention relates to methods of producing 56) References Cited transgenic plants by using vectors containing Gp2 promoter Sequences.
    [Show full text]
  • Identification of Foxr2 As an Oncogene in Medulloblastoma
    Published OnlineFirst March 5, 2014; DOI: 10.1158/0008-5472.CAN-13-1523 Cancer Tumor and Stem Cell Biology Research Identification of FoxR2 as an Oncogene in Medulloblastoma Hideto Koso1,2, Asano Tsuhako1, Eli Lyons1, Jerrold M. Ward2, Alistair G. Rust3, David J. Adams3, Nancy A. Jenkins2,4, Neal G. Copeland2,4, and Sumiko Watanabe1 Abstract Medulloblastoma is the most common pediatric brain tumor, and in 25% of cases, it is driven by aberrant activation of the Sonic Hedgehog (SHH) pathway in granule neuron precursor (GNP) cells. In this study, we identified novel medulloblastoma driver genes through a transposon mutagenesis screen in the developing brain of wild-type and Trp53 mutant mice. Twenty-six candidates were identified along with established driver genes such as Gli1 and Crebbp. The transcription factor FoxR2, the most frequent gene identified in the screen, is overexpressed in a small subset of human medulloblastoma of the SHH subtype. Tgif2 and Alx4, 2 new putative oncogenes identified in the screen, are strongly expressed in the SHH subtype of human medulloblas- toma. Mutations in these two genes were mutually exclusive with mutations in Gli1 and tended to cooccur, consistent with involvement in the SHH pathway. Notably, Foxr2, Tgif2, and Alx4 activated Gli-binding sites in cooperation with Gli1, strengthening evidence that they function in SHH signaling. In support of an oncogenic function, Foxr2 overexpression transformed NIH3T3 cells and promoted proliferation of GNPs, the latter of which was also observed for Tgif2 and Alx4. These findings offer forward genetic and functional evidence associating Foxr2, Tgif2, and Alx4 with SHH subtype medulloblastoma.
    [Show full text]
  • Osrrm, a Spen-Like Rice Gene Expressed Specifically in the Endosperm
    Shi-Yan Chen et al. npg Cell Research (2007) 17:713-721. npg713 © 2007 IBCB, SIBS, CAS All rights reserved 1001-0602/07 $ 30.00 ORIGINAL ARTICLE www.nature.com/cr OsRRM, a Spen-like rice gene expressed specifically in the endosperm Shi-Yan Chen1, 2, Zong-Yang Wang1, Xiu-Ling Cai1 1National Key Laboratory of Plant Molecular Genetics, Shanghai Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 300 Fenglin Road, Shanghai 200032, China; 2Graduate School of the Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100039, China We used the promoter trap technique to identify a rice plant, named 107#, in which the β-glucuronidase (GUS) reporter gene was expressed specifically in the endosperm. A single copy of the T-DNA was inserted into the plant genome, and a candidate gene OsRRM was identified by the insertion. The OsRRM promoter directed GUS expression specifically in rice endosperm, analogous to the GUS expression pattern observed in 107#. OsRRM is a single-copy gene in rice and encodes a nuclear protein containing 1 005 amino-acid residues with two RNA recognition motifs and one Spen paralog and ortholog C-terminal domain. Western blot analysis confirmed that the OsRRM protein was specifically expressed in rice endosperm. Ectopic expression of OsRRM in transgenic plants led to abnormalities, such as short stature, retarded growth and low fructification rates. Our data, in conjunction with the reported function ofSpen genes, implicated OsRRM in the regulation of cell development in rice endosperm. Keywords: RRM, Spen, promoter trap, GUS, rice Cell Research (2007) 17:713-721.
    [Show full text]
  • Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) a Target Enabling Package (TEP)
    Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) A Target Enabling Package (TEP) Gene ID / UniProt ID / EC 8767 / O43353 / - Target Nominator SGC Internal Nomination SGC Authors Peter Canning, Daniel M. Pinkas, Joshua C. Bufton, Sarah Picaud, Jennifer A. Ward, Catherine Rogers, Benedict-Tilman Berger, Stefan Knapp, Susanne Muller-Knapp, Paul E. Brennan, Kilian V. M. Huber, Panagis Filippakopoulos, Alex N. Bullock Collaborating Authors Matous Hrdinka1, Qui Ruan2, Chalada Suebsuwong3, Lisa Schlicher1, Bing Dai2, Jenny L. Maki2, Soumya S. Ray4, Danish Saleh5, Sameer Nikhar6, Tobias Schwerd7, Holm H.Uhlig7, Gregory D. Cuny6, Alexei Degterev2, Mads Gyrd-Hansen1 Target PI Alex N. Bullock (SGC Oxford) Therapeutic Area(s) Inflammatory diseases Disease Relevance Mutations in the NOD2-RIPK2 pathway identify RIPK2 a potential therapeutic target in auto-immune and inflammatory conditions such as Crohn’s disease, Blau syndrome, early-onset osteoarthritis and multiple sclerosis. Date Approved by TEP Evaluation 13th June 2018 Group Document version Version 3 Document version date October 2020 Citation Peter Canning, Daniel M. Pinkas, Joshua C. Bufton, Sarah Picaud, Jennifer A. Ward, Catherine Rogers, … Alex N. Bullock. (2018). Human Receptor- Interacting Serine/Threonine-Protein Kinase 2 (RIPK2); A Target Enabling Package. Zenodo. http://doi.org/10.5281/zenodo.1344501 Affiliations 1. Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford 2. Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine 3. Department of Chemistry, Science and Research Building 2, University of Houston 4. Center for Neurologic Diseases, Department of Neurology, Brigham & Women's Hospital and Harvard Medical School 5. Medical Scientist Training Program and Program in Neuroscience, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine 6.
    [Show full text]
  • Systems Consequences of Amplicon Formation in Human Breast Cancer
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Research Systems consequences of amplicon formation in human breast cancer Koichiro Inaki,1,2,9 Francesca Menghi,1,2,9 Xing Yi Woo,1,9 Joel P. Wagner,1,2,3 4,5 1 2 Pierre-Etienne Jacques, Yi Fang Lee, Phung Trang Shreckengast, Wendy WeiJia Soon,1 Ankit Malhotra,2 Audrey S.M. Teo,1 Axel M. Hillmer,1 Alexis Jiaying Khng,1 Xiaoan Ruan,6 Swee Hoe Ong,4 Denis Bertrand,4 Niranjan Nagarajan,4 R. Krishna Murthy Karuturi,4,7 Alfredo Hidalgo Miranda,8 andEdisonT.Liu1,2,7 1Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Genome, Singapore 138672, Singapore; 2The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06030, USA; 3Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA; 4Computational and Systems Biology, Genome Institute of Singapore, Genome, Singapore 138672, Singapore; 5Universite de Sherbrooke, Sherbrooke, Quebec, J1K 2R1, Canada; 6Genome Technology and Biology, Genome Institute of Singapore, Genome, Singapore 138672, Singapore; 7The Jackson Laboratory, Bar Harbor, Maine 04609, USA; 8National Institute of Genomic Medicine, Periferico Sur 4124, Mexico City 01900, Mexico Chromosomal structural variations play an important role in determining the transcriptional landscape of human breast cancers. To assess the nature of these structural variations, we analyzed eight breast tumor samples with a focus on regions of gene amplification using mate-pair sequencing of long-insert genomic DNA with matched transcriptome profiling. We found that tandem duplications appear to be early events in tumor evolution, especially in the genesis of amplicons.
    [Show full text]
  • The Estrogen Receptor Cofactor SPEN Functions As a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers
    Author Manuscript Published OnlineFirst on August 21, 2015; DOI: 10.1158/0008-5472.CAN-14-3475 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. SPEN is a tumor suppressor in ERα positive breast cancers Title The estrogen receptor cofactor SPEN functions as a tumor suppressor and candidate biomarker of drug responsiveness in hormone-dependent breast cancers. Running Title SPEN is a tumor suppressor in ERα positive breast cancers Authors and affiliations: Légaré, Stéphanie1,2, Cavallone, Luca2, Mamo, Aline2, Chabot, Catherine2, Sirois, Isabelle1,2, Magliocco, Anthony3, Klimowicz, Alexander3, Tonin, Patricia N.4, Buchanan, Marguerite2, Keilty, Dana1,2, Hassan, Saima1,2, Laperrière, David5, Mader, Sylvie5,6, Aleynikova, Olga2, Basik Mark1,2 Keywords - Transcriptional corepressor - Tumor suppressor gene - Estrogen receptor positive breast cancers - Endocrine resistance Financial support • Stéphanie Légaré • Supported by a McGill Integrated Cancer Research Training Program studentship (FRN53888) and a doctoral award from the Fonds de recherche du Québec – Santé. • Isabelle Sirois • Recipient of the Eileen Iwanicki postdoctoral fellowship in Breast Cancer Research from the Canadian Institutes of Health Research in partnership with the Breast Cancer Society of Canada. 1 Dept of Surgery and Oncology, McGill University, Montréal, Québec, Canada. 2 Dept of Oncology and Surgery, Lady Davis Institute for Medical Research, Montréal, Québec, Canada. 3 Dept of Pathology, University of Calgary, Calgary, Alberta, Canada. 4 Depts of Human Genetics and Medicine, McGill University and The Research Institute of the McGill University Health Centre, Montréal, Québec, Canada. 5 Institut de recherche en immunologie et cancérologie, IRIC, Montréal, Québec, Canada. 6 Dept de Biochimie, Université de Montréal, Montréal, Québec, Canada.
    [Show full text]
  • Macrophage Activation JUNB Is a Key Transcriptional Modulator Of
    JUNB Is a Key Transcriptional Modulator of Macrophage Activation Mary F. Fontana, Alyssa Baccarella, Nidhi Pancholi, Miles A. Pufall, De'Broski R. Herbert and Charles C. Kim This information is current as of October 2, 2021. J Immunol 2015; 194:177-186; Prepublished online 3 December 2014; doi: 10.4049/jimmunol.1401595 http://www.jimmunol.org/content/194/1/177 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2014/12/03/jimmunol.140159 Material 5.DCSupplemental References This article cites 40 articles, 7 of which you can access for free at: http://www.jimmunol.org/content/194/1/177.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 2, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology JUNB Is a Key Transcriptional Modulator of Macrophage Activation Mary F. Fontana,* Alyssa Baccarella,* Nidhi Pancholi,* Miles A.
    [Show full text]
  • TGIF2 Monoclonal Antibody (M06), Clone 6A8
    TGIF2 monoclonal antibody (M06), clone 6A8 Catalog # : H00060436-M06 規格 : [ 100 ug ] List All Specification Application Image Product Mouse monoclonal antibody raised against a partial recombinant Western Blot (Cell lysate) Description: TGIF2. Immunogen: TGIF2 (NP_068581, 131 a.a. ~ 236 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Sequence: SMPLHSGQGEKPAAPFPRGELESPKPLVTPGSTLTLLTRAEAGSPTGG LFNTPPPTPPEQDKEDFSSFQLLVEVALQRAAEMELQKQQDPSLPLLHT enlarge PIPLVSENP Western Blot (Recombinant protein) Host: Mouse Immunofluorescence Reactivity: Human Isotype: IgG2a Kappa Quality Control Antibody Reactive Against Recombinant Protein. Testing: enlarge Sandwich ELISA (Recombinant protein) enlarge ELISA Western Blot detection against Immunogen (37.4 KDa) . Storage Buffer: In 1x PBS, pH 7.4 Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Instruction: MSDS: Download Datasheet: Download Applications Western Blot (Cell lysate) Page 1 of 3 2020/3/20 TGIF2 monoclonal antibody (M06), clone 6A8 Western Blot analysis of TGIF2 expression in IMR-32 ( Cat # L008V1 ). Protocol Download Western Blot (Recombinant protein) Protocol Download Immunofluorescence enlarge this image Immunofluorescence of monoclonal antibody to TGIF2 on HeLa cell. [antibody concentration 10 ug/ml] Sandwich ELISA (Recombinant protein) Detection limit for recombinant GST tagged TGIF2 is approximately 0.3ng/ml as a capture antibody. Protocol Download ELISA Gene Information Entrez GeneID: 60436 GeneBank NM_021809 Accession#: Protein NP_068581 Accession#: Gene Name: TGIF2 Gene Alias: - Page 2 of 3 2020/3/20 Gene TGFB-induced factor homeobox 2 Description: Omim ID: 607294 Gene Ontology: Hyperlink Gene Summary: The protein encoded by this gene is a DNA-binding homeobox protein and a transcriptional repressor. The encoded protein appears to repress transcription by recruiting histone deacetylases to TGF beta- responsive genes.
    [Show full text]
  • Targeting RIP Kinases in Chronic Inflammatory Disease
    biomolecules Review Targeting RIP Kinases in Chronic Inflammatory Disease Mary Speir 1,2, Tirta M. Djajawi 1,2 , Stephanie A. Conos 1,2, Hazel Tye 1 and Kate E. Lawlor 1,2,* 1 Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia; [email protected] (M.S.); [email protected] (T.M.D.); [email protected] (S.A.C.); [email protected] (H.T.) 2 Department of Molecular and Translational Science, Monash University, Clayton, VIC 3168, Australia * Correspondence: [email protected]; Tel.: +61-85722700 Abstract: Chronic inflammatory disorders are characterised by aberrant and exaggerated inflam- matory immune cell responses. Modes of extrinsic cell death, apoptosis and necroptosis, have now been shown to be potent drivers of deleterious inflammation, and mutations in core repressors of these pathways underlie many autoinflammatory disorders. The receptor-interacting protein (RIP) kinases, RIPK1 and RIPK3, are integral players in extrinsic cell death signalling by regulating the production of pro-inflammatory cytokines, such as tumour necrosis factor (TNF), and coordinating the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome, which underpin patholog- ical inflammation in numerous chronic inflammatory disorders. In this review, we firstly give an overview of the inflammatory cell death pathways regulated by RIPK1 and RIPK3. We then discuss how dysregulated signalling along these pathways can contribute to chronic inflammatory disorders of the joints, skin, and gastrointestinal tract, and discuss the emerging evidence for targeting these RIP kinases in the clinic. Keywords: apoptosis; necroptosis; RIP kinases; chronic inflammatory disease; tumour necrosis factor; Citation: Speir, M.; Djajawi, T.M.; interleukin-1 Conos, S.A.; Tye, H.; Lawlor, K.E.
    [Show full text]